RPAM
RYTM icon

Rhenman & Partners Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,000
Closed -$3.75M – 101
2025
Q4 		$3.75M Hold
35,000
– – 0.35% 71
2025
Q3 		$3.53M Buy
+35,000
New +$3.25M 0.39% 69

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Rhenman & Partners Asset Management's RYTM Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 35,000 shares — an estimated $3.75M sold.

Rhenman & Partners Asset Management first reported a position in RYTM in Q3 2025 and held it in 2 quarters. The position peaked at $3.75M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Rhenman & Partners Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 35,000 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.75M.
  • Rhenman & Partners Asset Management first reported a position in Rhythm Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Rhythm Pharmaceuticals position peaked at $3.75M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.